BioCentury | Nov 18, 2016
Company News

uniQure restructuring news

...AAV-S100A1 to treat congestive heart failure (CHF). The product is an AAV vector carrying the S100 calcium binding protein A1 (S100A1)...
...Business: Gene/Cell therapy, Pharmaceuticals Chris Lieu AAV-S100A1 AAV2-GDNF AMT-060 AMT-110 AMT-130 Bristol-Myers Squibb Co. uniQure N.V. Factor IX Glial cell-derived neurotrophic factor (GDNF) Huntingtin (HTT) N-acetylglucosaminidase alpha (NAGLU) S100 calcium binding protein A1 (S100A1)...
BioCentury | Nov 15, 2016
Company News

uniQure paring down gene therapy portfolio

...candidate AAV-S100A1 to treat congestive heart failure (CHF). The product is an AAV vector expressing S100 calcium binding protein A1 (S100A1)...
...to $7.73 on Tuesday. Chris Lieu AAV-S100A1 AAV2-GDNF AMT-060 AMT-110 AMT-130 Bristol-Myers Squibb Co. uniQure N.V. Factor IX Glial cell-derived neurotrophic factor (GDNF) Huntingtin (HTT) N-acetylglucosaminidase alpha (NAGLU) S100 calcium binding protein A1 (S100A1)...
BioCentury | Apr 13, 2015
Company News

uniQure N.V, Bristol-Myers deal

...for multiple disease targets. The deal includes AAV-S100A1 , an adeno-associated virus (AAV) vector expressing S100 calcium binding protein A1 (S100A1)...
...in preclinical testing to treat congestive heart failure by restoring the heart’s ability to synthesize S100A1...
...the potential for target-exclusive collaboration in other cardiovascular and non-cardiovascular diseases on nine targets, excluding S100A1...
BioCentury | Apr 10, 2015
Financial News

uniQure raises $88.5M in follow-on

...technology platform for up to 10 targets. The deal includes a program targeting S100 calcium binding protein A1 ( S100A1...
BioCentury | Apr 7, 2015
Top Story

BMS teams with uniQure for CV gene therapies

...gained through its acquisition of InoCard last August. uniQure's AAV-S100A1 therapy, an adeno-associated virus expressing S100A1...
...million within three months, by which time it will select three targets in addition to S100A1...
...partnership progresses. uniQure is eligible for $254 million in development and regulatory milestones for the S100A1...
BioCentury | Aug 18, 2014
Finance

Highlights of weekly biotech stock moves

...shareholders will also be eligible to receive undisclosed milestones and royalties. InoCard's gene therapy, AAV- S100A1...
...Ib trial slated to begin in 2016. InoCor is an adeno-associated virus (AAV) vector expressing S100 calcium binding protein A1 (S100A1)...
BioCentury | Aug 18, 2014
Company News

InoCard, uniQure deal

...will also be eligible to receive undisclosed milestones and royalties. InoCard’s gene therapy, InoCor ( AAV-S100A1...
...Ib trial slated to begin in 2016. InoCor is an adeno-associated virus (AAV) vector expressing S100 calcium binding protein A1 (S100A1)...
BioCentury | Jul 28, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

...Summary Licensing status Publication and contact information Cardiovascular disease Heart failure S100 calcium binding protein A1 (S100A1) Pig studies suggest S100A1...
...infarction (MI)-induced heart failure, cardiac injection of an adeno-associated virus serotype 9 (AAV9) vector expressing S100A1...
...compared with injection of an inactive control vector. Ongoing work includes IND-enabling studies of the AAV9-S100A1...
Items per page:
1 - 8 of 8